You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

160 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia
Exceptional Access Program
    venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of unresectable advanced hepatocellular carcinoma according to clinical criteria
Mar 2023
Guidelines and Advice
Status: Current
ID: GL 8-10
Version: N/A
Feb 2020
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma
May 2024
Cette page s’adresse aux personnes ayant récemment reçu un diagnostic de leucémie aiguë lymphoblastique (LAL)
Drug
Other Name(s): Lorbrena®
Feb 2025
Trouvez des liens vers des pages d’information sur les soins de cancérologie offerts en Ontario pendant la pandémie de COVID-19.
Vous trouverez ici des liens vers des pages d’information sur les soins de cancérologie offerts en Ontario pendant la pandémie de COVID-19.

Pages